New drug cocktail aims to tackle tough stomach cancer

NCT ID NCT01991379

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two drugs, MEK162 and imatinib (Gleevec), in people with advanced gastrointestinal stromal tumor (GIST). The first part finds the safest dose, and the second part checks how well the combo shrinks tumors. About 75 participants will take part, including those who have not had treatment before.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MEK162 (binimetinib) and imatinib mesylate (Gleevec)
What this could lead to: If successful, this combination could offer a new first-line treatment option for advanced GIST, potentially improving response rates and delaying disease progression.
What could go wrong: This is an early-phase trial (Ib/II) with a small number of participants, so the benefits and risks are not yet fully known. The combination may cause side effects or not work better than imatinib alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMOR (GIST) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastrointestinal stromal tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROINTESTINAL STROMAL TUMOR (GIST)

Contacts and locations

Locations

Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.